4-Epidoxycycline: an alternative to doxycycline to control gene expression in conditional mouse models.
Since the pioneering work by Gossen and Bujard in 1992 demonstrating the usefulness of the Escherichia coli derived tet resistance operon for regulating gene expression a large collection of doxycycline-controlled transgenic mice has been established. Gene switching in eukaryotic tissue culture cells or mice requires administration of tetracycline, anhydrotetracycline or doxycycline to efficiently inactivate the transactivator protein tTA (TET-OFF system) or alternatively to activate the reverse transactivator protein rtTA (TET-ON system). However, the antibiotic activity of doxycycline can create an imbalance of the intestinal flora, resulting in diarrhoea and in a smaller number of animals in colitis. Previous studies reported that 4-epidoxycycline (4-ED), a hepatic metabolite of doxycycline, does not function as an antibiotic in mice. This gave us the idea that 4-ED might be useful for controlling gene expression in mice without the unwanted antibiotic side effect. To study the applicability of 4-ED for control of gene expression we used cell lines expressing the oncogene HER2 under control of tTA (TET-OFF) as well as rtTA (TET-ON). 4-ED and doxycycline were similarly efficient in switching on or -off HER2 expression. In vivo we used a conditional mouse model that allows switching off HER2 in tumor tissue. We show that (i) doxycycline, 7.5mg/ml in drinking water (used as a positive control), (ii) 4-ED, 7.5mg/ml in drinking water, (iii) 4-ED, 10mg/kg body weight, s.c., and (iv) anhydrotetracycline, 10mg/kg, s.c. (used as a second positive control), were similarly efficient. Using mice with tumor volumes of 1.6cm(3) all four schedules led to a tumor remission of more than 95% within 7 days. In conclusion, 4-ED is similarly efficient as doxycycline to control gene expression in vitro and in mice. Since 4-ED lacks the antibiotic activity of doxycycline it may help to avoid adverse side effects and selection of resistant bacteria.
Eger
K
K
Institute of Pharmacy, University of Leipzig, Germany.
Hermes
M
M
Uhlemann
K
K
Rodewald
S
S
Ortwein
J
J
Brulport
M
M
Bauer
A W
AW
Schormann
W
W
Lupatsch
F
F
Schiffer
I B
IB
Heimerdinger
C K
CK
Gebhard
S
S
Spangenberg
C
C
Prawitt
D
D
Trost
T
T
Zabel
B
B
Sauer
C
C
Tanner
B
B
Kolbl
H
H
Krugel
U
U
Franke
H
H
Illes
P
P
Madaj-Sterba
P
P
Bockamp
E O
EO
Beckers
T
T
Hengstler
J G
JG
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004318:Doxycycline / Q000008:administration & dosage*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008822:Mice, Transgenic; D041681:NIH 3T3 Cells; D051381:Rats; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D013237:Stereoisomerism; D013754:Tetracyclines / Q000008:administration & dosage; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D004318:Doxycycline; D018719:Erb-b2 Receptor Tyrosine Kinases; D013754:Tetracyclines; C016229:4-epianhydrotetracycline